anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Obesity has been linked to abnormal frontal function, including the white matter fibers of anterior portion of the corpus callosum, which is crucial for information exchange within frontal cortex. However, alterations in white matter anatomical connectivity between corpus callosum and cortical regions in patients with obesity have not yet been investigated. Thus, we enrolled 72 obese and 60 age-/gender-matched normal weight participants who underwent clinical measurements and diffusion tensor imaging. Probabilistic tractography with connectivity-based classification was performed to segment the corpus callosum and quantify white matter anatomical connectivity between subregions of corpus callosum and cortical regions, and associations between corpus callosum-cortex white matter anatomical connectivity and clinical behaviors were also assessed. Relative to normal weight individuals, individuals with obesity exhibited significantly greater white matter anatomical connectivity of corpus callosum-orbitofrontal cortex, which was positively correlated with body mass index and self-reported disinhibition of eating behavior, and lower white matter anatomical connectivity of corpus callosum-prefrontal cortex, which was significantly negatively correlated with craving for high-calorie food cues. The findings show that alterations in white matter anatomical connectivity between corpus callosum and frontal regions involved in reward and executive control are associated with abnormal eating behaviors.
The Greater-Bay-Area Healthy Aging Brain Study (GHABS), a community-based longitudinal cohort study, aimed to characterize of Alzheimer's disease in South China's Aging Population, was launched in May 2021 in Shenzhen. The GHABS project was approved by the Shenzhen Bay Laboratory's and the collaborated hospitals' Ethical Committees. Each participant signed the written informed consent of the GHABS project before enrollment. The participants who met the inclusion and exclusion requirements were informed about the baseline and follow-up examinations. From 2021 to 2026, the GHABS cohort will recruit 1400 individuals aged 55 and older, including 1100 CU older adults, 200 MCI patients, and 100 dementia patients.

All the GHABS participants will undergo cognitive assessments, genetic screening, and blood sample collection. Some will have CSF collection, stool sample collection, MRI scanning, Aβ PET scanning, and tau PET scanning. All baseline examinations will be completed within three months. At follow-up, clinical assessments and blood sample collection will be conducted annually. CSF sample collection, MRI scan, Aβ PET scan, and tau PET scan are evaluated every two years.
We present two rare cases of p67phox-deficient chronic granulomatous disease (CGD) caused by compound heterozygous mutations in the NCF2 gene. They developed cervical lymphadenitis as the initial manifestation of CGD but had distinct clinical progressions. Patient 1 presented with aspergillous meningitis, an extremely rare manifestation of neurological involvement in CGD, which has not been reported before. Patient 2 presented with non-infectious inflammatory lymphadenitis is also very rare and has not been reported previously. These cases emphasize the importance of considering p67phox-deficient CGD in children with late-onset invasive fungal infections and non-infectious inflammatory lesions. Additionally, we also reviewed previous reports of Chinese patients with P67phox-Deficient CGD. Our objective is to raise awareness about the clinical, diagnostic, and genetic characteristics of P67phox-deficient CGD in China, to reduce misdiagnosis and improve the management and prognosis of the disease.
Treating co-occurring cannabis and tobacco use disorders might reduce the health burdens associated with both substances. However, few studies have evaluated pharmacological interventions, in combination with behavioral treatment, to address co-occurring cannabis and tobacco use; these are limited by high participant attrition, poor adherence to interventions, and lack of control. Pilot, eight week, open-label, within-subject cross over trial of four weeks of standard clinical care (SCC) in an outpatient substance use disorder treatment program and four weeks of SCC and varenicline among current and former tobacco smokers with frequent cannabis use. Participants were recruited from an urban, outpatient substance use disorder treatment program that offers both intensive behavioral counseling and medications for opioid use disorder (MOUD). Participants were randomized to receive either SCC or SCC and varenicline first and then were crossed over to receive the opposite intervention. The study consisted of two 4-week treatment periods with no washout period. Outcomes are reported in pooled analyses of all participants in each treatment phase.
The invention provides a spray -dried powder containing vancomycin hydrochloride and an industrial preparation method thereof. The industrial preparation method comprises the following steps: a vancomycin hydrochloride solution with chromatographic purity being not lower than 95% is used, a stabilizer and a solubilizer are added to raise stability and concentration of a concentrated solution, concentration of vancomycin hydrochloride can be raised to 20-30%, and spray-draying is carried out at the concentration so as to obtain the spray-dried powder containing vancomycin hydrochloride with impurity B being less than or equal to 1.5%. Stability problem of the vancomycin hydrochloride solution at high concentration is solved, and the concentration of vancomycin hydrochloride before spray is raised to 20-30%. Thus, spray-drying efficiency is greatly raised, and bulk density of an aseptic bulk drug also can be raised at high concentration of vancomycin hydrochloride such that split charging is easier. Rising of impurity content is controlled, and dissolving property of a finished product is raised. Product quality is improved. Processing step is shortened. Product yield is enhanced, and cost is reduced. It is easy to realize industrial large-scale production.
Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide and a substantial global health burden. Surgery is the only possible way to cure gastric cancer, however, more than 80% of the Chinese patients are diagnosed at advanced stages. Locally advanced esophagogastric junction and gastric cancer (cT3-4aNxM0 or cT2N+M0) could be cured by multi-disciplinary therapies including surgery, chemotherapy and radiotherapy. Neoadjuvant chemotherapy can downstage T and N stage, treated distant micrometastases early before local therapy has begun, and finally improve the long-term survival. However, the therapeutic effects remain unsatisfactory. PD-1 antibody has demonstrated its efficacy in metastatic gastric cancer and has been proved to be effective in neoadjuvant setting in lung cancer and melanoma. Combination of perioperative PD-1 antibody and chemotherapy for locally advanced esophagogastric junction and gastric cancer could be a novel therapy to increase response rate and reduce recurrence rate. JS001 in this study is a Chinese anti-PD-1 monoclonal antibody for injection which has been approved for melanoma. This study is a multi-center, open-label, randomized phase II clinical trial to evaluate safety and efficacy of JS001 in combination with perioperative chemotherapy in locally advanced esophagogastric junction and gastric cancer. Differences in gut microbiome and tumor immune microenvironment were detected to screen people who were more sensitive to immunotherapy.
The invention provides a preparation containing spirulina phatensis polysaccharide and cynomorium songaricum polysaccharide and manufacture method thereof and application. The preparation is prepared by adding a stabilizing agent, acidity regulator, a flavoring agent and preservative after spirulina phatenisis polysaccharide and cynomorium songaricum polysaccharide are dissolved in distilled water. The formula is 40mg/ml-260mg/ml of the spirulina phatensis, 60mg/ml-300mg/ml of the cynomorium songaricum polysaccharide, 6mg/ml-62mg/ml of the stabilizing agent, 0.1mg/ml-5mg/ml of the acidity regulator, 0.1mg/ml-15mg/ml of the flavoring agent and 0.1mg/ml-0.3mg/ml of the preservative. The spirulina phatenisis polysaccharide is free of harmful smell. The acidity regular and the flavoring agent are added so that smell and taste of the preparation can be improved and therefore the preparation is good in taste and stability. Oral liquid is prepared by the spirulina phatensis polysaccharide and the cynomorium songaricum polysaccharide so that absorption to polysaccharide of a human body is improved, synergy effect of the two kinds of polysaccharide is improved, and the preparation has the functions of promoting protein synthesis, anti-fatigue and enhancing body immunity capacity. The preparation is capable of obviously improving inhibition ratio of cancer cells and is suitable for cancer patients.
OBJECTIVES: Nutrition plays a vital role in the outcome of critical illness in children, particularly those with acute kidney injury. Currently, there are no established guidelines for children with acute kidney injury treated with continuous kidney replacement therapy. Our objective was to create clinical practice points for nutritional assessment and management in critically ill children with acute kidney injury receiving continuous kidney replacement therapy.
METHODS: An electronic search using PubMed and an inclusive academic library search (including MEDLINE, Cochrane, and Embase databases) was conducted to find relevant English-language articles on nutrition therapy for children (<18 y of age) receiving continuous kidney replacement therapy.
RESULTS: The existing literature was reviewed by our work group, comprising pediatric nephrologists and experts in nutrition. The modified Delphi method was then used to develop a total of 45 clinical practice points. The best methods for nutritional assessment are discussed. Indirect calorimetry is the most reliable method of predicting resting energy expenditure in children on continuous kidney replacement therapy. Schofield equations can be used when indirect calorimetry is not available. The non-intentional calories contributed by continuous kidney replacement therapy should also be accounted for during caloric dosing. Protein supplementation should be increased to account for the proteins, peptides, and amino acids lost with continuous kidney replacement therapy.
CONCLUSIONS: Clinical practice points are provided on nutrition assessment, determining energy needs, and nutrient intake in children with acute kidney injury and on continuous kidney replacement therapy based on the existing literature and expert opinions of a multidisciplinary panel.
A required number of consecutive patients meeting the inclusion criteria were recruited for this study. After written informed consent patient demographic and baseline clinical characteristics were obtained. Inclusion criteria for the study were either gender between 18 to 80 years of age, diagnosed with congestive heart failure (CHF) with NYHA class II-IV, and LVEF ≤ 40%. Pre-inclusion safety parameters were patients who were stable on any dose of beta-blockers, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) prior to enrolment in the study. Patients with a baseline diagnosis of Hyperkalemia, hypotension, renal dysfunction, and a history of hypersensitivity to the active substances, Sacubitril/Valsartan, or to any of the excipients or drugs of similar chemical classes were excluded from the study.

All the recruited patients were prescribed Sacubitril/Valsartan 100mg/200mg twice a day (BID) for 6 weeks. A weekly telephonic follow-up was made to assess the patient's medication adherence level using the Dose-Nonadherence scale. All the patients were kept under a close follow-up for 6 weeks period and at the end of 12 weeks of medication, the safety and tolerability outcomes were assessed as per the operational definition.
The present invention relates to methods and pharmaceutical compositions for treating cancer in a subject in need thereof. The inventors believe that the low activity of Serine Hydroxymethyltransferase (SHMT) is due to poor availability of pyridoxal 5' -phosphate (PLP) in cancer cellsWill result in exposure to 5-fluorouracil (FUra) and exposure to N5-formyltetrahydropteroylglutamic acid (5-HCO-H) 4 PteGlu; folinic acid) insufficient growth inhibition in cancer cells of FUra in combination. Cancer cell lines grown in vitro were exposed to FUra as a single dose, and folinic acid-containing FUra in combination with high PLP concentrations. The inventors demonstrated a synergistic and additive interaction of folinic acid and PLP combinations on FUra cytotoxicity in HT29, HCT116 and L1210 cancer cells. Murine studies with high doses of pyridoxamine or pyridoxine showed that intracellular PLP levels were elevated to near or above the Kd levels reported for cofactor binding to SHMT, suggesting that modulation of fluoropyrimidine by vitamin B6 may be achieved in vivo. Accordingly, the present invention relates to an anti-tumor pharmaceutical combination comprising (i) fluoropyrimidine, (ii) B6 isovitamin, and optionally (iii) folic acid, and the use of said combination for the treatment of cancer in a subject in need thereof.
Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 2 million cells per kg wt suspended in 100 ml of physiological saline solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid-Citospin.
Duchenne muscular dystrophy (DMD) is the most common lethal inherited disorder worldwide. Despite the exponential increase in our understanding of the disorder since the discovery and characterization of the causative gene and its product dystrophin in 1987, current therapeutic management remains largely supportive. Awaiting a final genetic cure to be available in the future, further investments in developing better drug therapies for DMD remain important. The effect of a high dose prednisone regimen will be evaluated in comparison to a daily dose regimen in a multi-center, randomized, double-blind placebo-controlled 4-arm study. Ambulant children aged 4-10 years with an established DMD diagnosis will be studied. Patients will undergo 2 screening evaluations within 1 week. Patients will be randomized into treatment groups on the second screening visit, followed by a 12-month treatment period. During the treatment period, patients will be evaluated at monthly intervals. The primary endpoints are percentage change in average muscle strength score and QMT performance for specific muscle groups. Secondary endpoints include timed function tests, functional grades for arms and legs, and pulmonary function tests.
ABSTRACT        The invention relates to new condensed as-triazine derivatives of the general formula /I/     /I/                             wherein Z represents a buta-1,3 dienyl group or a group of the formula /a/, /b/, /c/ or /d/                            /a/                 /b/         /c/               /d/       R1 denotes a C1-10 alkyl group, an oxo group or a C6-10 aryl or C6-10 aryl-/C1-3 alkyl/ group optionally substituted by one or more identical or different substituents selected from the group consisting of amino, nitro, C1-?  alkyl, C1-6 alkoxy, hydroxy and halogen, R2 stands for hydrogen, C1-10 alkyl or amino, R3 represents hydrogen, C1-10 alkyl or C6-10 aryl or C6-10 aryl-/C1-3 alkyl/ optionally substituted by one or more identical or different substituents selected from the group consisting of nitro, amino, C1-6 alkyl, C1-6 alkoxy, hydroxy and halogen, X- denotes an anion, and n is O or 1, with the proviso that if n is 0, R1 is other than an oxo group and R1 and R2 form together a double bond, and with the further provisos that if n is 1, R1 represents an oxo group and the symbols R? and R?  are not present, and if Z is a buta-1,3-dienyl group and R1 denotes an oxo group, R3 is other than unsubstituted phenyl.      The new compounds of the general formula /I/ can be prepared by cyclizing the compounds of the general formula /II/ or /V/, wherein R1, Z, R3 and R7  have the above defined meanings, R4 is a leaving group and R7 represents hydrogen or C1-10 alkyl.        The new compounds of the general formula /I/ possess a valuable antidepressant effect and can advantageously be used in the therapy.
Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. Lubiprostone acts by specifically activating ClC-2, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A-independent fashion.

By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Patch clamp cell studies in human cell lines have indicated that the majority of the beneficial biological activity of lubiprostone and its metabolites is observed only on the apical (luminal) portion of the gastrointestinal epithelium.

Lubiprostone, via activation of apical ClC-2 channels in intestinal epithelial cells, bypasses the antisecretory action of opiates that results from suppression of secretomotor neuron excitability.

Activation of ClC-2 by lubiprostone has also been shown to stimulate recovery of mucosal barrier function and reduce intestinal permeability via the restoration of tight junction protein complexes in ex vivo studies of ischemic porcine intestine.
PURPOSE:To obtain the beads by forming liquid drops from a liquid suspension in which relatively large particles are suspended and which has a thixotropic property and curing these liquid drops. CONSTITUTION:The liquid suspension 18 in a liquid tank 16 is introduced to plunger pumps 22, from which the liquid is delivered through discharge ports 68 toward liquid drop forming nozzles 24. The liquid drops discharged from the liquid drop forming nozzles 24 are thereafter cured to the beads having a desired size. Since the liquid suspension 18 is kept directly stirred near the suction of the plunger pumps 22, even the liquid suspension 18 having the large suspended particles and the high thixotropic property can be smoothly introduced to the plunger pumps 22 and the liquid drop are stably and surely formed from the liquid drop forming nozzles 24. The sizes of the liquid drops are uniformized and, in addition, the easy regulation of the sizes thereof is possible as well. The beads having the desired sizes are produced if such liquid drops are solidified.
This is a randomized, double-blind, placebo-controlled, parallel group study, designed to assess the effectiveness \& safety of the B. longum 1714™ strain, when consumed once daily, on sleep quality. The 8-week intervention study will be conducted in otherwise healthy participants with a Pittsburgh Sleep Quality Index (PSQI) score of greater than, or equal to 5, a HADS-A and HAD-D score less than or equal to 14 and an Insomnia Severity Index of less than 11. Participants (N=90) will be pre-screened online, then visit the study site 4 times during the course of the 8 - 10 weeks' study (2 weeks screening period, followed by 8-week intervention). The first visit will be for screening, second visit will be baseline (and start of intervention - either active or placebo), third visit will be mid-intervention, and fourth visit will be at the end of intervention. Questionnaires will be administered at visit 2, 3 and 4, and research blood and saliva will also be collected at these time points. Hair sample will be taken at visit 2 and 4 while stool sample will be collected at visit 4. Participants will wear an actigraph and fill in a sleep eDiary for the whole intervention period (from visit 2 to visit 4).
It will involve an initial ramping up to 0.5 mA and then a ramp down to 0 mA for the remainder of each treatment. The same number of sessions as active tDCS will be administered.
Urological Chronic Pelvic Pain Syndromes (UCPPS) are characterized by pelvic pain with concurrent urinary symptoms. Broadly, UCPPS comprise Interstitial Cystitis/Painful Bladder SyndromeBladder Pain Syndrome (IC/BPS) in men and women, and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) in men. IC is a debilitating bladder disorder characterized by urinary urgency, frequency, and pain. The presentation of symptoms can be quite variable among patients, suggesting that IC is a multi-factorial syndrome with several proposed etiologies, some of which may be interrelated.1 BPS as defined by the International Continence Society, is "the complaint of suprapubic pain related to bladder filling, accompanied by other symptoms, such as increased daytime and night-time frequency, in the absence of proven urinary infection or other obvious pathology."2 BPS is a clinical description of disease based on the patient's symptoms, and does not depend on urodynamic or cystoscopic findings. These symptoms may be related to IC, although diagnostic criteria are still lacking for this entity, and the relationship between BPS and IC is not clear. After the initiation phase for the MAPP SPS Study, it became clear that many of the hypotheses being proposed required well-characterized healthy "normal" controls that lack urologic pain as well as other study related symptoms/conditions. This second phase is enriched with pre-defined subgroups and a longer follow-up period which will allow further investigation of clinical and biologic factors associated with worsening and/or improvement of reported urinary and non-urinary symptoms.
AIMS: To assess toxicity and patient quality of life after stereotactic body radiotherapy (SBRT) to oligoprogressive disease (OPD) in patients with metastatic castrate-resistant prostate cancer (CRPC) on androgen receptor targeted agents (ARTA).
MATERIAL AND METHODS: This phase II trial enrolled patients with metastatic CRPC with ≤ 2 oligoprogressive lesions in bone, lymph node, lung, or prostate. All patients were receiving systemic treatment with abiraterone or enzalutamide at the time of oligoprogression. All patients received SBRT to the OPD site(s) and continued the current ARTA. Patients received 30 Gy in 5 fractions (alternate days) to the OPD site. The primary endpoint of the trial is to assess if SBRT to OPD sites results in progression free survival of >6 months. The primary endpoint for this toxicity analysis is the rate of grade 3 or higher adverse events at any timepoint up to 6 months after SBRT. Secondary endpoints included comparing pre- and post-SBRT patient-related outcomes reported using visual analogue scale scores and EQ-5D health questionnaire.
RESULTS: Forty enrolled patients had at least 6 months of follow-up at the time of analysis. Grade 3 or higher toxicity from any cause recorded using common terminology criteria for adverse events and radiation therapy oncology group was found in 8/40 (20%) of patients, but only 1/40 (2.5%) was deemed possibly related to SBRT. There was no significant difference in mean EQ5D visual analogue scale score from baseline to each timepoint after SBRT (p = 0.449).
CONCLUSION: In this prospective phase II clinical trial for OPD whilst on ARTA in the CRPC setting, we report low grade ≥ 3 toxicity after SBRT. There is no discernible change in patient-reported quality of life due to SBRT treatment. The final results of progression-free survival and toxicity of SBRT treatment will be reported once further follow-up is complete.
The goal of EMDR is to help manage physical and mental unpleasant experiences due to hypertension. The intervention group received EMDR therapy included eight phases, each lasting 60-90 minutes, and the intervention consisted of four weekly. In this study, a Nurse practitioner trained in EMDR performs an intervention in an outpatient clinic's quiet, empty room.